CoChat
Sign Up
Cited by 52Advanced Glycation End Products researchDiabetes Management and ResearchChronic Kidney Disease and Diabetes

Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients

Open access
Guerin-Dubourg, Alexis, Cournot, Maxime, Planesse, Cynthia, Debussche, Xavier, Meilhac, Olivier, Rondeau, Philippe, Bourdon, Emmanuel·2017·BioMed Research International
DOI 10.1155/2017/7989180PMC PMC5736945
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: Diabetes is a major health problem associated with hyperglycemia and chronically increased oxidative stress and enhanced formation of advanced glycation end-products (AGEs). The aim of this study was to determine whether oxidative plasma biomarkers in diabetic patients could be evidenced and associated with vascular complications. METHODS: Oxidative stress biomarkers such as thiols, ischemia-modified albumin (IMA), glycated albumin (GA), fructosamine, and AGEs were measured in 75 patients with poorly controlled type 2 diabetes (HbA1c > 7.5%) with (44) or without (31) vascular disease and in 31 nondiabetic controls. RESULTS: Most biomarkers of oxidation and glycation were significantly increased in diabetic patients in comparison with nondiabetics. Fructosamines, GA, IMA, and AGEs were positively correlated and levels of fluorescent AGEs were significantly increased in the plasma from patients presenting vascular complication. CONCLUSIONS: These results bring new evidence for the potential interest of glycated albumin, oxidative stress, and glycoxidation parameters in the monitoring of type 2 diabetic patients. Furthermore, it emphasizes fluorescent AGEs as a putative indicator for vascular event prediction in diabetic patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2017/7989180

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Guerin-Duborg et al. used an AGE-ELISA Kit preferentially quantifying CML and found no differences between non-diabetic subjects and T2D patients, or between T2D patients with and without vascular diseases.

    “Guerin-Duborg and colleagues used an AGE-ELISA Kit preferentially quantifying CML and revealed no differences between non-diabetic subjects and T2D patients as well as T2D patients with and without vascular diseases.”

    From Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases (2021) · cites this paper as [160]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. [2]Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the kelly west award lecture 2008 Diabetes Care 2010 33 2 442 449 10.2337/dc09-0749 2-s2.0-75149129619 20103560 PMC2809299 · DOI
  2. [3]Favier F. Jaussent I. Le Moullec N. Prevalence of Type 2 diabetes and central adiposity in La Réunion Island, the REDIA study Diabetes Research and Clinical Practice 2005 67 3 234 242 10.1016/j.diabres.2004.07.013 2-s2.0-13844250568 15713356 · DOI
  3. [4]Wolff S. P. Jiang Z. Y. Hunt J. V. Protein glycation and oxidative stress in diabetes mellitus and ageing Free Radical Biology & Medicine 1991 10 5 339 352 10.1016/0891-5849(91)90040-a 2-s2.0-0025853670 1855674 · DOI
  4. [6]Rondeau P. Bourdon E. The glycation of albumin: structural and functional impacts Biochimie 2011 93 4 645 658 10.1016/j.biochi.2010.12.003 2-s2.0-79952446703 21167901 · DOI · Paper page
  5. [7]Baraka-Vidot J. Guerin-Dubourg A. Bourdon E. Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin Biochimie 2012 94 9 1960 1967 2-s2.0-84864246770 10.1016/j.biochi.2012.05.017 22627382 · DOI
  6. [8]Baraka-Vidot J. Guerin-Dubourg A. Dubois F. Payet B. Bourdon E. Rondeau P. New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities Biochimica et Biophysica Acta 2013 1830 6 3532 3541 10.1016/j.bbagen.2013.01.019 2-s2.0-84876005975 23376313 · DOI
  7. [9]Guerin-Dubourg A. Catan A. Bourdon E. Rondeau P. Structural modifications of human albumin in diabetes Diabetes and Metabolism 2012 38 2 171 178 2-s2.0-84859716804 10.1016/j.diabet.2011.11.002 22349032 · DOI
  8. [10]Chilelli N. C. Burlina S. Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view Nutrition, Metabolism & Cardiovascular Diseases 2013 23 10 913 919 10.1016/j.numecd.2013.04.004 2-s2.0-84878894541 23786818 · DOI
  9. [11]Pitocco D. Tesauro M. Alessandro R. Ghirlanda G. Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications International Journal of Molecular Sciences 2013 14 11 21525 21550 10.3390/ijms141121525 2-s2.0-84886816599 24177571 PMC3856020 · DOI
  10. [12]Bar-Or D. Lau E. Winkler J. V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report Journal of Emergency Medicine 2000 19 4 311 315 10.1016/s0736-4679(00)00255-9 2-s2.0-0033765993 11074321 · DOI
  11. [13]Bar-Or D. Rael L. T. Bar-Or R. The cobalt-albumin binding assay: insights into its mode of action Clinica Chimica Acta 2008 387 1-2 120 127 10.1016/j.cca.2007.09.018 2-s2.0-35748962954 17964561 · DOI
  12. [14]Roy D. Kaski J. C. Ischemia-modified albumin: the importance of oxidative stress Journal of the American College of Cardiology 2007 49 24 2375 2376 10.1016/j.jacc.2007.04.010 2-s2.0-34249980088 17572257 · DOI
  13. [15]Ashfaq S. Abramson J. L. Jones D. P. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults Journal of the American College of Cardiology 2006 47 5 1005 1011 2-s2.0-33644582884 10.1016/j.jacc.2005.09.063 16516085 · DOI
  14. [16]Stauber R. E. Spindelboeck W. Haas J. Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure Therapeutic Apheresis and Dialysis 2014 18 1 74 78 10.1111/1744-9987.12024 2-s2.0-84893817191 24499087 · DOI
  15. [17]Zagorchev L. Seal C. E. Kranner I. Odjakova M. Redox state of low-molecular-weight thiols and disulphides during somatic embryogenesis of salt-treated suspension cultures of Dactylis glomerata L. Free Radical Research 2012 46 5 656 664 2-s2.0-84859022216 10.3109/10715762.2012.667565 22348546 · DOI
  16. [19]Thornalley P. J. Rabbani N. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry - a user's perspective Biochimica et Biophysica Acta - General Subjects 2014 1840 2 818 829 10.1016/j.bbagen.2013.03.025 2-s2.0-84890123209 23558060 · DOI · Paper page
  17. [20]Ho E. Karimi Galougahi K. Liu C. C. Bhindi R. Figtree G. A. Biological markers of oxidative stress: applications to cardiovascular research and practice Redox Biology 2013 1 1 483 491 10.1016/j.redox.2013.07.006 24251116 PMC3830063 · DOI
  18. [21]Debussche X. Collin F. Fianu A. Structured self-management education maintained over two years in insufficiently controlled type 2 diabetes patients: the ERMIES randomised trial in reunion island Cardiovascular Diabetology 2012 11, article 91 10.1186/1475-2840-11-91 2-s2.0-84864445516 PMC3537557 22856504 · DOI
  19. [22]Ellman G. L. Tissue sulfhydryl groups Archives of Biochemistry and Biophysics 1959 82 1 70 77 2-s2.0-3042934967 10.1016/0003-9861(59)90090-6 13650640 · DOI
  20. [23]Chesne S. Rondeau P. Armenta S. Bourdon E. Effects of oxidative modifications induced by the glycation of bovine serum albumin on its structure and on cultured adipose cells Biochimie 2006 88 10 1467 1477 10.1016/j.biochi.2006.05.011 2-s2.0-33750614168 16814919 · DOI
  21. [24]Lee E. Eom J.-E. Jeon K.-H. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay Journal of Pharmaceutical and Biomedical Analysis 2014 91 17 23 2-s2.0-84892473600 10.1016/j.jpba.2013.12.003 24434278 · DOI
  22. [25]Baraka-Vidot J. Planesse C. Meilhac O. Glycation alters ligand binding, enzymatic, and pharmacological properties of human albumin Biochemistry 2015 54 19 3051 3062 2-s2.0-84929577149 10.1021/acs.biochem.5b00273 25915793 · DOI
  23. [26]Brownlee M. The pathological implications of protein glycation Clin Invest Med 1995 18 275 81 8549013
  24. [27]Son S. M. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes Diabetes and Metabolism Journal 2012 36 3 190 198 2-s2.0-84864633135 10.4093/dmj.2012.36.3.190 22737658 PMC3380122 · DOI
  25. [28]Lyons T. J. Glycation and oxidation: a role in the pathogenesis of atherosclerosis The American Journal of Cardiology 1993 71 6 B26 B31 10.1016/0002-9149(93)90142-Y 2-s2.0-0027537768 8434558 · DOI
  26. [29]Kaefer M. Piva S. J. de Carvalho J. A. M. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus Clinical Biochemistry 2010 43 4-5 450 454 10.1016/j.clinbiochem.2009.11.018 2-s2.0-76749084277 19968982 · DOI
  27. [30]Sinha M. K. Gaze D. C. Tippins J. R. Collinson P. O. Kaski J. C. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention Circulation 2003 107 19 2403 2405 2-s2.0-0037842058 10.1161/01.CIR.0000072764.18315.6B 12742986 · DOI
  28. [31]Thomas M. C. Woodward M. Neal B. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes Diabetes Care 2015 38 10 1891 1897 10.2337/dc15-0925 26253728 · DOI
  29. [32]Brownlee M. Cerami A. Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease Diabetes/Metabolism Reviews 1988 4 5 437 451 2-s2.0-0023803371 10.1002/dmr.5610040503 2850143 · DOI
  30. [33]Kent M. J. C. Light N. D. Bailey A. J. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro Biochemical Journal 1985 225 3 745 752 2-s2.0-0022006780 10.1042/bj2250745 3919711 PMC1144652 · DOI
  31. [34]Sell D. R. Lapolla A. Odetti P. Fogarty J. Monnier V. M. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM Diabetes 1992 41 10 1286 1292 2-s2.0-0026675759 10.2337/diabetes.41.10.1286 1397702 · DOI
  32. [35]Hegab Z. Gibbons S. Neyses L. Mamas M. A. Role of advanced glycation end products in cardiovascular disease World Journal of Cardiology 2012 4 4 90 102 10.4330/wjc.v4.i4.90 22558488 PMC3342583 · DOI
  33. [36]Hanssen N. M. J. Engelen L. Ferreira I. Plasma levels of advanced glycation endproducts Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies The Journal of Clinical Endocrinology and Metabolism 2013 98 8 E1369 E1373 10.1210/jc.2013-1068 2-s2.0-84881496313 23780372 · DOI
  34. [38]Pia de la Maza M. Garrido F. Escalante N. Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications Journal of Diabetes Mellitus 2012 02 02 221 226 10.4236/jdm.2012.22035 · DOI
  35. [39]Sims T. J. Rasmussen L. M. Oxlund H. Bailey A. J. The role of glycation cross-links in diabetic vascular stiffening Diabetologia 1996 39 8 946 951 2-s2.0-0029893422 10.1007/s001250050536 8858217 · DOI
  36. [40]Yoshida N. Okumura K.-I. Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes Metabolism: Clinical and Experimental 2005 54 3 345 350 10.1016/j.metabol.2004.09.014 2-s2.0-13844266010 15736112 · DOI · Paper page
  37. [41]Zhou Y. Yu Z. Jia H. Association of serum pentosidine with arterial stiffness in hemodialysis patients Artificial Organs 2010 34 3 193 199 2-s2.0-77949702399 10.1111/j.1525-1594.2009.00801.x 20447043 · DOI
  38. [42]Raposeiras-Roubín S. Rodiño-Janeiro B. K. Paradela-Dobarro B. Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome PLoS ONE 2013 8 9 10.1371/journal.pone.0074302 e74302 2-s2.0-84884167477 PMC3772878 24058542 · DOI
  39. [43]Ma S. G. Wei C. L. Hong B. Yu W. N. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease Clinics (Sao Paulo) 2011 66 1677 80 22012037 PMC3180151
  40. [44]Katakami N. Kaneto H. Shimomura I. Carotid ultrasonography: a potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients Journal of Diabetes Investigation 2014 5 1 3 13 10.1111/jdi.12106 2-s2.0-84896697634 24843729 PMC4025224 · DOI
  41. [45]Gunduz A. Turedi S. Mentese A. Ischemia-modified albumin levels in cerebrovascular accidents American Journal of Emergency Medicine 2008 26 8 874 878 2-s2.0-52949101055 10.1016/j.ajem.2007.11.023 18926343 · DOI
  42. [46]Zhong Y. Wang N. Xu H. Hou X. Xu P. Zhou Z. Ischemia-modified albumin in stable coronary atherosclerotic heart disease: clinical diagnosis and risk stratification Coronary Artery Disease 2012 23 8 538 541 10.1097/MCA.0b013e328358a5e9 2-s2.0-84869501318 22936021 · DOI
  43. [47]Liao J. Farmer J. Arterial stiffness as a risk factor for coronary artery disease. Current atherosclerosis reports 2014 16 2 p. 387 2-s2.0-84906930045 10.1007/s11883-013-0387-8 24402301 · DOI

Cited by

Sorted by citations

Authors
Guerin-Dubourg, A., Cournot, M., Planesse, C., Debussche, X., Meilhac, O., Rondeau, P., & Bourdon, E.
Affiliations
  • Université de La Réunion, INSERM, UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France
  • Inserm (FR)
  • Centre Hospitalier Universitaire de La Réunion (RE)
Corresponding author
  • Rondeau, Philippe
  • Bourdon, Emmanuel
ORCID
Venue
BioMed Research International
Publisher
Wiley
Published
2017
Volume
2017
Pages
1-10
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
DOI
10.1155/2017/7989180
PMC
PMC5736945
OpenAlex
W2771880510
Cited by
52
References
3
Citations by year
2025: 6 · 2024: 5 · 2023: 4 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 8 · 2018: 1
FWCI
4.09
Type
journal article
Language
en
Open access
Licence
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministère de l’Enseignement Supérieur et de la Recherche
  • Ministère de l’Outre-Mer
  • Conseil Régional de La Réunion and Europe
  • University of La Réunion
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
advanced glycation end products, type 2 diabetes, diabetic vascular complications, oxidative stress, glycated albumin, ischemia-modified albumin, fructosamine, thiols, glycated proteins, hyperglycemia, biomarkers
MeSH terms
Serum Albumin, Human, Glycated Serum Albumin, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Oxidation-Reduction, Pilot Projects, Serum Albumin, Biomarkers, Case-Control Studies, Glycation End Products, Advanced, Oxidative Stress, Fructosamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review